SPDR S&P Biotech ETF (XBI) Dividend Safety Gauge & 10-Year DRIP Compounder
SPDR S&P Biotech ETF (XBI) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
$10,000 Compounded Over 10 Years → $21,992
Cash-Fortress Compounders: Collecting Safe Yield & Upside in XBI & Top A-Rated Leaders
- ✓12-month Bull/Base/Bear fair-value walkthrough on XBI and its top sector rival
- ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
- ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
XBI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XBI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XBI. Explore sector supply chains on /butterfly.
XBI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDDoes XBI pay a dividend and is it safe?
SPDR S&P Biotech ETF (XBI) offers a 1.3% cash dividend yield ($2.03 annualized) and 3.1% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.